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Abstract
Background: A compound herbal formulation (POL4) has been used in the indigenous system of medicine to treat
cardiometabolic disorders like diabetes and associated hypertension. POL4 and most of its constituents have not
been studied widely for its therapeutic use in hypertension. This study is aimed to determine the efficacy and
possible insight into mechanism(s) for the medicinal use of POL4 and its ingredients in hypertension.
Methods: The aqueous methanolic extracts of POL4 (POL4.Cr) and its components [Cichorium intybus (Ci.Cr),
Gymnema sylvestre (Gs.Cr), Nigella sativa (Ns.Cr) and Trigonella foenum graecum (Tfg.Cr)] were tested for blood
pressure lowering activity in anaesthetized Sprague-Dawley rats. To assess the vasomodulatory effect, isolated
tissue experiments were performed on rat aortic strips using isometric force transducer coupled with PowerLab
data acquisition system.
Results: Administration of POL4 to rats caused a dose-dependent (1–100 mg/kg) fall in mean arterial pressure
(MAP) with maximum effect of 85.33 ± 1.76% at 100 mg/kg, similar to the effect of verapamil. All ingredients of
POL4 also decreased blood pressure with varying efficacy in following order Ns.Cr ≅ Ci.Cr > Tfg.Cr > Gs.Cr. In rat
aortic preparations, POL4 and its ingredients inhibited K
+ (80 mM)-induced contractions, Ci.Cr was the most potent
followed by Ns.Cr > Tfg.Cr > Gs.Cr ≅ POL4. Against phenylephrine (P.E) contractions, Ci.Cr and Tfg.Cr exhibited
complete relaxation, while POL4.Cr, Gs.Cr and Ns.Cr showed vasomodulatory effect. The Ca
++ antagonist activity
was confirmed when POL4 and its ingredients shifted Ca
++ concentrations-response curves to the right in a manner
similar to that of verapamil. On baseline of rat aorta, the parent formulation and its ingredients (except Tfg.Cr)
exhibited partially phentolamine (1 μM)-sensitive vasoconstriction.
Conclusion: These data show that POL4 and its constituents possess blood pressure lowering activity mediated
through inhibition of Ca++ influx via membranous Ca++ channels and receptor (α-adrenergic) operated pathways.
Thus, this study provides a rationale to the medicinal use of POL4 and its constituents in hypertension.
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Background
Cardiovascular disorders (CVDs) are huge disease burden
worldwide [1]. Hypertension, dyslipidemia and endothelial
dysfunctions are the major pathologies of commonly
prevailing CVDs [2]. Hypertension is a silent killer, which is
known to cause around 9.8 million deaths annually [3].
Pakistan is one of the South Asian countries where around
18 million people at the age of fifteen and above are living
with hypertension. Out of these, around 70% population is
even unaware about the disease status, while only 3%
successfully control blood pressure with regular medication
[4–6]. Multiple antihypertensive therapeutic agents are
available to combat this deadly disorder, however, their
high cost and life-long use of the medication along with
associated multiple adverse effects ultimately results in pa-
tient unaffordability and poor-compliance [7]. The current
strategy to defeat chronic non-communicable disorders is
changing throughout the world. The use of alternative ap-
proaches, particularly medicinal remedies and supple-
ments [8, 9], have become popular over the past three
decades. Around 80% of people worldwide rely on natural
products [10] for therapeutic purpose. Treating chronic
disorders like hypertension or diabetes, the herbal remed-
ies are considered relatively safe, affordable and easily
accessible. The relative safety of natural products when
used for longer duration might be because of the presence
of synergistic and/or side effects neutralizing constituents
inbuilt in medicinal herbs [11]. In our settings due to cul-
tural acceptance, people prefer to use herbal remedies for
the treatment of various chronic ailments like gastro-
intestinal [12], respiratory tract [13], endocrine (diabetes)
[14] and cardiovascular disorders [15]. Despite using indi-
vidual herbs to treat different ailments, there are multiple
evidences supporting therapeutic use of compound
formulations in the treatment of hypertension and dyslip-
idemia. Some of the combined formulations like Sharbat
Abresham, Hab Fishar for hypertension, Arq-Sheer-
Morakkab as cardiotonic, Muffrahe-Barid-Sada and Arq--
Gazar Ambari as anti-palpitant [16] are used in indigenous
system of medicine in Pakistan. POL4, an indigenous poly-
herbal formulation containing four edible medicinal herbs
(Cichorium intybus L., Gymnema sylvestre R. Br., Nigella
sativa L., and Trigonella foenum graecum L.) is also popular
for its medicinal use in cardiometabolic disorders, however,
no study is available to rationalize its medical use in cardio-
metabolic disorders like hypertension.
The ingredients of POL4: C. intybus (family: Asteraceae)
commonly called Chicory or Kasni, G. sylvestre (family:
Asclepiadaceae) known as Gurmar booti, N. sativa (family:
Ranunculaceae) referred as Black cumin or Kalonji and T.
foenum graecum (family: Fabaceae) vernacularly called as
Fenugreek or Methi are popular for their medicinal use as
cardiotonic, antihypertensive and cadio-depressant [17]. C.
intybus (coumarins, sterols, tannins, triterpene cichoridiol,
lupeol, sesquiterpene glycoside, caffeic acid and cichotybo-
side) [18], G. sylvestre (gymnemasides anthraquinone,
stigmasterol, betaine, quercitol and gymnemagenin) [19], N.
sativa (thymoquinone, α-pinene, p-cymnene, carvacrol,
terpineol, nigellicimine and nigellidine) [20] and T. foenum
graecum (trigonelline, cholin, gentian, carpaine and
4-hydroxyisoleucine and diosgenin) [21] have been found
enriched with variety of phytochemicals. Most of the deter-
mined phytochemicals on the part of the components of
POL4 are also known for their diverse health benefits
including their effectiveness in cardiovascular disorders
[22–27]. Though detailed studies are lacking to justify the
cardiovascular benefits of POL4 and its ingredients, the
available data is providing some support to individual com-
ponents {C. intybus [27, 28], G. sylvestre [19, 29] and T.
foenum graecum [30, 31]} for their utility in cardiovascular
disorders with exception of N. sativa which has been stud-
ied widely. Despite the availability of ample data on N.
sativa and its constituents (thymoquinone, α-pinene and
p-cymene) for their effectiveness in hypertension [24–26,
32–34], the effect of its seed extract with holistic picture on
vascular and atrial preparations is yet to be determined for
its modulating role on vascular resistance and cardiac out-
put. This study has been designed to provide an evidence
to the medicinal use of POL4 and its ingredients in cardio-
vascular disorders like hypertension with a prime objective
to determine the blood pressure lowering effects and the
possible insight into mechanism(s). While the secondary
objective was to compare the efficacy of ingredients with
the parent formulation to justify the use of this formulation
in hypertension and/or to suggest modification in its
current composition. The in-vivo assays were carried out in
rat as per their similarity with human cardiovascular
system, which are commonly employed worldwide to
determine antihypertensive efficacy of the test compounds
[35–37], while isolated tissue experiments were conducted
in rat (aorta) and guinea-pig (atria) tissues.
Methods
Preparation of aqueous-methodic extracts of POL4 and its
ingredients
The plant materials were purchased from “Rehmania
Pinsar Store” Sargodha and the samples were identified
by Dr. Muhammad Amin Ullah Shah, Assistant
Professor of Botany, Department of Botany, University
of Sargodha, Sargodha, Pakistan. The respective samples
have been submitted in the herbarium at University of
Sargodha with voucher numbers as: [seeds of N. sativa
(Malik-632), C. intybus (Malik-633), T. foenum graecum
(Malik-634) and leaves of G. sylvestre (Malik-635)]. The
individual plant materials and in combination (POL4)
were subjected for extraction. For preparation of the
crude extract, 1 kg of powder of each plant material and
1 kg of POL4 (all ingredients in equal proportions) were
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soaked, respectively, in aqueous methanol (30: 70) for
3 days with occasional shaking. The methanol of analyt-
ical grade was purchased from Merck KGaA, Darmstadt,
Germany. The first filtrate obtained was subjected to
filter using muslin cloth and Whatman (Maidstone, UK)
No.1 filter paper simultaneously. The procedure was re-
peated twice and all filtrates were combined and evapo-
rated under rotary evaporator (BUCHI, Switzerland)
[38]. The filtrates were then air dried and the respective
percentage yields were calculated for the crude extracts
of polyherbal formulation POL4.Cr (16% w/w), C.
intybus, Ci.Cr (11% w/w), G. sylvestre, Gs.Cr (18% w/w),
N. sativa, Ns.Cr (12% w/w) and T. foenum graecum,
Tfg.Cr (17.5% w/w).
Drugs and chemicals
Verapamil hydrochloride, potassium chloride, acetylcho-
line chloride, phenylephrine, phentolamine, norepineph-
rine, isoproterenol and calcium chloride were purchased
from Sigma Chemical Company, St. Louis, MO, U.S.A.
Glucose, sodium chloride, magnesium sulphate, magne-
sium chloride, potassium dihydrogen phosphate, sodium
bicarbonate and sodium dihydrogen phosphate were
from E. Merck, Darmstadt, Germany. All chemicals used
were of the highest purity grade. Physiological salt solu-
tions were prepared fresh in distilled water on the day of
experiment, while stock solutions of all chemicals and
extracts were constituted in distilled water/saline and
stored at −20 °C, while required dilutions were prepared
fresh on the day of the experiment.
Animals, diet and experimental protocol
The Sprague-Dawley (SD) rats weighing 180–250 g and
locally bred guinea pigs weighing 450–550 g healthy of
either sex housed at the animal house of Aga Khan
University, Karachi, were used in this study. Animals
were either sourced from PCSIR (Pakistan Council of
Scientific and Industrial Research, Karachi or Dow
University of Health Sciences Karachi and have also
been managed to be bred at the animal house of Aga
Khan University. The animals were housed in a
temperature maintained facility (23 ± 5 °C, 55 ± 5%, rela-
tive humidity) with 12-hr light/dark cycle, kept in plastic
cages with sawdust (renewed at every two days). Animals
had free access to standard diet [(g/kg): flour 380, fiber
380, molasses 12, sodium chloride 5.8, nutrivet-L 2.5,
potassium metabisulphate 1.2, vegetable oil 38, fish meal
170 and powdered milk 150] and tap water, and were ac-
climatized for 5 to 7 days before starting experiment.
The experimental protocols were approved (57-ECACU-
BBS-15) by Ethics Committee for Animal Care and Use
(ECACU) of the Aga Khan University, Karachi.
Phytochemical screening
Phytochemical screening of the crude extract of POL4
and its constituents were carried out for the presence of
flavonoids, tannins, saponins, alkaloids, anthraquinones
and coumarins by using an earlier described method
with slight modification [39].
Determination of total phenolic contents
Quantitative determination of phenolics contents of the
aqueous methanolic extracts of compound herbal for-
mulation POL4 and its ingredients were carried out by
an earlier method [40] with slight modification. Briefly,
1 ml of Folin-Ciocalteu reagent was added to the test
material solution containing 1 mg in a volumetric flask
and adjusted to 46 ml with distilled water. After 3 min,
3 ml of Na2CO3 (2%) was added to the mixture, which
was afterward kept for 2 h at room temperature with
continuous shaking on a shaker. The absorbance was
measured at 760 nm by using spectrophotometer (Model
DU-730, Beckman Instruments Inc, Palo Alto, CA,
USA). Total phenolic content of the test materials were
expressed as mg equivalent of gallic acid equivalent/g of
the dried extract.
Determination of total flavonoid contents
Amount of total flavonoid compounds of the aqueous
methanolic extracts of POL4 and its ingredients were de-
termined as described previously [41]. Around 1.5 ml of
the test material solution was added to an equal volume
of solution of 2% AlCl3.6H2O in methanol. The mixture
was vigorously shaken and absorbance was recorded at
367 nm after 10 min of incubation. The absorption mea-
sured using a spectrophotometer (Model DU 730). Fla-
vonoid contents were expressed as mg of quercetin
equivalent/g of the extract.
In-vivo blood pressure measurement in anaesthetized rats
SD rats (180–250 g) of either sex were used by following
an earlier method [42]. The animals were randomly se-
lected and were anesthetized with an intraperitoneal injec-
tion of thiopental sodium (purchased from Pharmacy of
Aga Khan University Hospital, Karachi, Pakistan) at a dose
of 40–70 mg/kg body weight. The arterial blood pressure
was recorded by cannulating carotid artery filled with hep-
arinized saline to a disposable blood pressure transducer
(model MLT 0699) attached with bridge amplifier and a
PowerLab data acquisition system (ADInstruments,
Australia). Jugular vein was cannulated to inject different
test material(s) to the animal. Before injecting 0.9% NaCl
(0.1 ml/kg, saline) or equal volume of test substance(s) to
rats, a period of about 10–15 min was given for
stabilization. Heparin was purchased from Pharmacy of
Aga Khan University Hospital, Karachi, Pakistan. Between
each injected dose, the arterial pressure was allowed to
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return to normal or resting level. Prior to the assessment
of the effect of the different doses (1–100 mg/kg) test ma-
terial(s), standard drugs responses like acetylcholine
(1 mg/kg) and norepinephrine (1 mg/kg) were given intra-
venously (jugular vein) to obtain the control responses.
The difference between the steady state values before and
after injection was recorded as the mean arterial pres-
sure (MAP). MAP was calculated by using the formula
PP = SP-DP where PP-pulse pressure, SP-systolic
pressure and DP-diastolic pressure.
Isolated rat aortic preparation
SD rats (180–250 g) of either sex were used randomly in
this study and were anesthetized using Isoflurane (2–5%
v/w) by inhalation in a closed chamber until achievement
of deep anesthesia. Isoflurane was purchased from
Pharmacy of Aga Khan University Hospital, Karachi,
Pakistan. Dissection was carried out to isolate thoracic
aortae and the aorta was cut into rings of around 2 to
3 mm. The rings were mounted in 5 ml water bath con-
taining Kreb’s solution at 37 °C and carbogen [O2 (95%)
and CO2 (5%)] was continuously supplied. The Kreb’s so-
lution was prepared freshly on the day of experiment
which consists of following ingredients in mM: NaCl
118.2, KCl 4.7, KH2PO4 1.3, MgSO4 1.2, NaHCO3 25.0,
Glucose 11.7 and CaCl2 2.5 with pH 7.4. A pre-load of 2 g
was provided as baseline tension and each tissue prepar-
ation was allowed to incubate for a period of 60 min. The
changes in isometric tension were recorded and analyzed
using the force transducer model (50–7905, Harvard Ap-
paratus, USA), linked with a Trans-bridge model TBM4M
and PowerLab data acquisition system (ML845, ADInstru-
ment). The tissues were stabilized with phenylephrine (P.E
1 μM). The test materials (0.003 to 10 mg/ml) were tested
for vasorelaxant potential against P.E (1 μM) and high K+
(80 mM)-induced contractions. For confirmation of
calcium channel blocking (CCB) like activity, the Ca++
concentration-response curves (CRCs) were produced in
Ca++-free medium in the absence and presence of test
material(s) to observe if there is a non-parallel shift in the
CRCs of Ca++ towards right with suppression of max-
imum response [15]. To determine the presence of vaso-
constrictor constituents in test material(s), experiments
were performed on resting baseline tone of the aortic
preparations. First, tissues were stabilized with P.E until
steady-state baseline tone; the vasoconstrictor effect of the
test material(s) was presented as percent of P.E- induced
contraction and has also been reproduced in the presence
of phentolamine (α-adrenergic receptor antagonist) to
identify its sensitivity with phentolamine.
Isolated guinea-pig atria
Guinea-pigs of either sex were euthanized followed by
anesthesia with Isoflurane. Dissection was carried out
quickly and carefully to isolate right atria. The isolated
atria was cleaned and mounted in 20 ml water bath con-
taining Kreb’s solution maintained at 32 °C. The bathing
solution was bubbled continuously with carbogen. The
atria as applied 1 g resting tension and allowed to beat
normally as it contains the pacemaker cells. Atrial tissue
was allowed for an equilibrium period of around 30 min
before application of any test material(s) or standard
drug(s) like isoproterenol (1 μM) and acetylcholine
(1 μM). A force-displacement transducer coupled to
PowerLab data acquisition system (ADInstrument,
Australia) was used to record the tension changes in the
tissues [43].
Data analysis
The experimental data presented as mean ± S.E.M
(standard error of mean), n = number of experiments
and EC50 (median effective concentration) values were
reflecting as the geometric means with CI (confidence
intervals) of 95%. Concentration response curves were
constructed and analyzed by non-linear regression
followed by sigmoidal curves. For determination of
significant differences, one way ANOVA (analysis of
variance) followed by Dunnet’s test or two-way ANOVA
followed by Bonferroni’s post-test correction or unpaired
t-test were applied. P values <0.05 were taken as signifi-
cantly different. GrpahPad Prism (Version 4.00) software
was used for constructing graphs and analysis.
Results
Phytochemical screening
Qualitative phytochemical screening of the aqueous-
methanolic extract of POL4 and its components have
shown the presence of flavonoids, tannins, saponins, al-
kaloids, anthraquinones and coumarins.
Total phenolic and flavonoid contents
Total phenolic and flavonoid contents of the aqueous-
methanolic extract of POL4 and its ingredients have
been found in varying proportion. Phenolic contents
were found in highest proportion in G. sylvestre followed
by Ci.Cr > POL4.Cr > Ns.Cr > Tfg.Cr (Table 1). While
flavonoids were found highest in T. foenum graecum
followed by Gs.Cr > POL4.Cr > Ci.Cr > Ns.Cr (Table 1).
Effect on blood pressure in anaesthetized rats
In normotensive anaesthetized SD rats, intravenous
administration of polyherbal formulation (POL4) and its
ingredients (C. intybus, G. sylvestre, N. sativa and T. foe-
num graecum) caused a dose-dependent (1, 3, 10, 30 and
100 mg/kg) fall in MAP (Fig. 1). Verapamil has also de-
creased MAP dose-dependently (0.1–10 mg/kg) as seen
in Fig. 1. The % maximum effects (Emax) of the parent
formulation, its ingredients and verapamil at respective
Malik et al. BMC Complementary and Alternative Medicine  (2017) 17:142 Page 4 of 12
tested concentrations have been listed together in Table 2.
The parent formulation has been found the most effective
followed by Ns.Cr ≅Ci.Cr > Tfg.Cr > Gs.Cr.
Effect on isolated rat aortic preparation
The vasomodulatory effect of parent polyherbal formula-
tion (POL4) and its ingredients (C. intybus, G. sylvestre,
N. sativa and T. foenum graecum) were tested against
high K+ (80 mM) and P.E (1 μM)-induced contractions,
while to determine the presence of vasospastic activity,
test materials were challenged on stabilized basal tone of
isolated rat aortic preparations. Against P.E-induced
contractions, POL4, G. sylvestre and N. sativa have
shown dual activities, initially vasoconstriction at 0.01–
1 mg/ml followed by relaxation at 3–10 mg/ml.
However, C. intybus and T. foenum graecum caused
complete relaxation of P.E-induced contractions at
0.03–10 mg/ml, similar to the activity pattern of verap-
amil (0.03–3 μM) as seen in Fig. 2. The summary of
vasomodulatory effects of POL4 and its ingredients has
been shared in upper panel of Table 3. Against high K
+-induced contractions, the parent formulation and its
ingredients caused inhibition at 0.01–10 mg/ml, similar
to the effect of verapamil at 0.03–3 μM as shown in
Fig. 2. Their respective EC50 values are presented in
Table 3. When tested on basal/resting tone of rat aorta,
except T. foenum graecum which showed activity pattern
as of verapamil, the parent formulation and its constitu-
ents exhibited vasoconstriction at higher concentrations
similar to the effect of phenylephrine. When reproduced
in tissues pretreated with phentolamine (1 μM), the ob-
served vasocontractile effects were found attenuated as
seen in Fig. 3. The % age maximum vasoconstriction
(Vmax) of POL4 and its elements in the absence and
presence of phentolamine has been listed in Table 4.
To confirm the Ca++ antagonist like activity, when the
CRCs of Ca++ were constructed in the absence and pres-
ence of increasing concentrations of POL4 and its
Table 1 Total phenolic and flavonoid contents of POL4 and its
ingredients
Test materials Total phenolic contents
(mg GAE/g of extract)
Total flavonoid contents
(mg QE/g of extract)
POL4.Cr 18.56 ± 1.0 66.68 ± 0.87
Ns.Cr 11.27 ± 0.76 17.19 ± 1.52
Ci.Cr 24.73 ± 0.20 64.86 ± 0.86
Tfg.Cr 10.15 ± 0.64 87.85 ± 0.50
Gs.Cr 39.88 ± 0.78 75.64 ± 0.70
Results represent mean ± SD of 3 measurements
Abbreviations: POL4.Cr the crude extract of polyherbal formulation, Ci.Cr the
crude extract of C. intybus, Gs.Cr the crude extract of G. sylvestre, Ns.Cr the
crude extract of N. sativa, Tfg.Cr the crude extract of T. foenum graecum, GAE
gallic acid equivalent, QE quercetin equivalent
Fig. 1 Blood pressure lowering effect of (a) the crude extract of
polyherbal formulation (POL4.Cr), (b) verapamil, (c) the crude extracts
of C. intybus (Ci.Cr), (d) G. sylvestre (Gs.Cr), (e) N. sativa (Ns.Cr) and (f)
T. foenum graecum (Tfg.Cr) in normotensive anesthetized rats. The
data depicts mean ± SEM of 3 to 5 individual experiments using 7 to
10 animals. ns, non-significant, *p < 0.05, **p < 0.01 and ***p <
0.001vs saline (0.1 ml/kg) used as control (One-way ANOVA followed
by Dunnett’s test)
Table 2 Percentage maximum drop in blood pressure (%Emax)
by the test materials in normotensive anesthetized rats
Test materials Concentration Emax
POL4.Cr 100 (mg/ml) 85.33 ± 1.76 (n = 4)
Verapamil 10 (μM) 86.66 ± 4.41ns (n = 4)
Ci.Cr 100 (mg/ml) 65.00 ± 2.88 **(n = 3)
Gs.Cr 30 (mg/ml) 53.33 ± 14.53**(n = 5)
Ns.Cr 100 (mg/ml) 70.00 ± 5.77 **(n = 5)
Tfg.Cr 100 (mg/ml) 48.5 ± 5.00**(n = 4)
Data represents mean ± SEM of 3 to 5 experiments. ns, non-significant,
**p < 0.01 vs POL4.Cr (One-way ANOVA followed by Dunnett’s test)
Abbreviations: POL4.Cr the crude extract of poly herbal formulation, Ci.Cr the
crude extract of C. intybus, Gs.Cr the crude extract of G. sylvestre, Ns.Cr the
crude extract of N. sativa, Tfg.Cr the crude extract of T. foenum graecum
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components, these produced a non-parallel rightward
shift in the concentration-related curves of Ca++ with
suppression of maximum effect at concentrations range
of 0.03–5 mg/ml, similar to verapamil (0.03 and 0.1 μM)
as seen in Fig. 4. The maximum contractions of Ca++ at
highest concentration in the absence and presence of
respective test material(s) is presented in Table 5.
Effect on isolated guinea-pig atria
In isolated guinea-pig atria, the parent formulation and
three of its constituents (C. intybus, G. sylvestre and T.
foenum graecum) completely depressed the force and
rate of spontaneously beating atria at concentrations
range (0.1–10 mg/ml) as shown in Fig. 5a and b, similar
to verapamil which also inhibited the force and rate of
atrial contraction at 0.01 to 1 μM (Fig. 5c). However, N.
sativa initially showed mild cardiac stimulation in terms
of an increase in the force of contraction followed by in-
hibition, while no accelerating effect was observed on
the rate of contraction of atria as seen in Fig. 5b. Table 6
shows respective EC50 values of parent formulation and
its ingredients against force and rate of contractions of
the isolated atrial tissues.
Discussion
On account of the medicinal use of POL4 and its the
ingredients in cardiometabolic disorders like diabetes
and associated hypertension [17], when tested in
anesthetized rats, POL4 and its ingredients attenuated
the mean arterial pressure (MAP) in a dose-dependent
manner. Interestingly, the parent formulation was found
the most effective followed by Ns.Cr ≅ Ci.Cr > Tfg.Cr >
Gs.Cr. Our findings on the part of N. sativa are in line
with earlier report on its antihypertensive efficacy [32].
However, this study is reporting for the first time, the
Fig. 2 Vasomodulatory effect of (a) the crude extract of polyherbal
formulation (POL4.Cr), (b) verapamil, (c) the crude extracts of C.
intybus (Ci.Cr), (d) G. sylvestre (Gs.Cr), (e) N. sativa (Ns.Cr) and (f) T.
foenum graecum (Tfg.Cr) against phenylephrine and K+ (80 mM)-
induced contractions in rat aortae. The data represent mean ± SEM
of 4 to 7 experiments using tissues of 5 to 6 animals. ns, non-
significant, *p < 0.05, **p < 0.01 and ***p < 0.001vs. baseline
(Unpaired t-test)
Table 3 Percentage maximum vasoconstriction (%Vmax) and EC50 values of the test materials against P. E or K
+ (80 mM)-induced
contractions in rat aortic preparations
Parameters Test materials
POL4 .Cr Verapamil Ci. Cr Gs. Cr Ns. Cr Tfg. Cr
Effect against P.E (1 μM)-induced
contractions
% Vmax/Conc. (mg/ml) 141.43 ± 4.63/1 - - 221.66 ± 15.89***/1 131.95 ± 6.95*/0.03 -
Complete inhibition with resultant
EC50 values with 95% confidence
interval
- 0.417 mg/ml
(0.31–0.54)
2.01 mg/ml
(1.62–2.49)
- - 2.29 mg/ml
(1.15–4.56)
Effect against K+ (80 mM)-induced
contractions
Complete inhibition with resultant
EC50 values
4.70 mg/ml
(3.94–5.60)
0.27 mg/ml
(0.18–0.39)
0.31 mg/ml
(0.19–0.52)
3.13 mg/ml
(2.15–4.56)
0.68 mg/ml
(0.41–1.14)
1.40 mg/ml
(0.91–2.15)
Data represents mean ± SEM of 4 to 7 experiments
Abbreviations: POL4.Cr the crude extract of poly herbal formulation, Ci.Cr the crude extract of C. intybus, Gs.Cr the crude extract of G. sylvestre, Ns.Cr the crude
extract of N. sativa, Tfg.Cr the crude extract of T. foenum graecum
*p < 0.05 and ***p < 0.001 vs. POL4.Cr (Unpaired t-test)
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blood pressure lowering efficacy of C. intybus and G.
sylvestre in normotensive rats. These findings are also
providing a rationale to their medicinal use as cardio-
tonic or hypotensive [17, 19]. The blood pressure lower-
ing effects are also in agreement with the prior findings
related to vasorelaxant mechanisms on the part of C.
intybus [27] and T. foenum graecum [30, 31], which
might be playing a pivotal role in overall effectiveness of
these plants in hypertension. On the contrary, Preuss et
al. [44] reported that G. sylvestre did not show antihy-
pertensive effect in spontaneously hypertensive rats,
however, we did find its efficacy but with varying pattern
Fig. 3 Vasoconstrictor effect of (a) POL4.Cr, (b) its ingredients, (c) verapamil and (d) phenylephrine (P.E) without and with phentolamine on basal
tone of rat aortae. The data show mean ± SEM of 4 to 8 experiments using tissues of 4 to 5 animals.*p < 0.05, **p < 0.01 and***p < 0.001 vs.
baseline effects, while #p < 0.05, ##p < 0.01 and ###p < 0.001 vs. vasoconstriction in the presence of phentolamine (Unpaired t-test). Abbreviations:
POL4.Cr, the crude extract of poly-herbal formulation; Ci, the crude extract of C. intybus; Gs, the crude extract of G. sylvestre; Ns, the crude extract
of N. sativa; Tfg, the crude extract of T. foenum graecum
Table 4 Percentage maximum vasoconstriction (%Vmax) of test materials without and with phentolamine in rat aortic tissues
Test materials Concentration producing Vmax %Vmax without phentolamine %Vmax with phentolamine (1 μM)
POL4.Cr 10 (mg/ml) 55 ± 2.88 27.5 ± 2.50
###
Ci.Cr 3 (mg/ml) 33.66 ± 7.53** Blocked###
Gs.Cr 3 (mg/ml) 113 ± 3.51*** 76.66 ± 3.33###
Ns.Cr 5 (mg/ml) 80.33 ± 2.60** 18.33 ± 4.41###
Tfg.Cr Did not exhibited any vasoconstriction
Verapamil Did not exhibited any vasoconstriction
P.E 1 (μM) 75.19 ± 2.16 *** Blocked###
Data represents mean ± SEM of 4 to 8 experiments
Abbreviations: POL4.Cr the crude extract of poly herbal formulation, Ci.Cr the crude extract of C. intybus, Gs.Cr the crude extract of G. sylvestre, Ns.Cr the crude
extract of N. sativa, Tfg.Cr the crude extract of T. foenum graecum, P.E Phenylephrine
ns, non-significant, **p < 0.01 and ***/###p < 0.001
* shows a comparison of %Vmax of test materials without phentolamine vs. POL4.Cr (One-way ANOVA followed by Dunnett’s test), while
# shows a comparison
between %Vmax values without phentolamine vs. respective %Vmax values with phentolamine (Unpaired t-test)
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in normotensive rats which needs further investigations
using multiple models and species to attest or oppose its
therapeutic utility in hypertension.
Blood pressure is the product of cardiac output and
peripheral resistance [45]. An increase in any of these
two determinants can develop hypertension. Antihyper-
tensive drugs target both components either alone or in
combination. The preferred approach would be to cause
a predominantly reduction in peripheral vascular resist-
ance along with cardiac output.
To explore the effect of parent formulation and its
components on vascular resistance, in pre-contracted rat
aortic preparations, POL4 and its ingredients caused in-
hibition of K+ (80 mM)-induced contractions, where
Ci.Cr was found the most potent followed by Ns.Cr >
Tfg.Cr > Gs.Cr ≅ POL4. Based on inhibitory effects of test
material(s) against K+ (80 mM)-induced contractions, to
further attest the presence of Ca++ antagonist like activ-
ity on the part of test material(s), the concentration-
response curves (CRCs) of Ca++ were constructed in the
absence and presence of different concentrations of
POL4 and its ingredients, respectively. All produced a
non-parallel rightward shift in CRCs of Ca++ with sup-
pression of the maximum effect, similar to activity pat-
tern of verapamil, a known Ca++ antagonist [46]. Against
phenylephrine (P.E)- induced contraction, C. intybus and
T. foenum graecum showed complete relaxation, how-
ever, POL4, G. sylvestre and N. sativa showed initially
Fig. 4 Concentration-response curves of Ca++ constructed in absence and presence of (a) the crude extract of polyherbal formulation (POL4.Cr),
(b) verapamil, (c) the crude extracts of C. intybus (Ci.Cr), (d) G. sylvestre (Gs.Cr), (e) N. sativa (Ns.Cr) and (f) T. foenum graecum (Tfg.Cr) in rat aortae.
The data denote mean ± SEM of 4 to 7 experiments using tissues of 4 to 6 animals ***p < 0.001 vs. Control CRCs of Ca++ (Two-way analysis of
variance (ANOVA) followed by Bonferroni’s post-test correction)
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vasoconstriction followed by relaxation at higher tested
concentrations. The inhibitory potential of POL4 and its
ingredients against K+ (80 mM) and P.E signify their
ability to interfere with Ca++ entry through voltage-
dependent channels (VDCs) and receptor-operated
channels (ROCs). This is evident as K+ (80 mM) and P.E
(1 μM) mediate contraction by influx of extracellular Ca
++ through VDCs and ROCs, respectively, resulting in
increased intracellular Ca++ levels trigging sustained
contractions [43, 47]. Based on observed (vasocon-
strictor and/or vasodilator) effects of test material(s) on
P.E-induced contractions, the parent formulation and its
ingredients were studied for the presence of vaso-
stimulant activity on the baseline status of isolated rat
aortic preparations. All exhibited vasoconstriction with
varying efficacy, being Gs.Cr the most potent followed
by Ns.Cr > POL4 > Ci.Cr), similar to the effect of phenyl-
ephrine. However, T. foenum graecum was devoid of any
vasoconstriction, similar to the effect of verapamil.
When these effects were studied in the presence of
phentolamine, an α- adrenergic antagonist, all showed
partial sensitivity to phentolamine except C. intybus
which was found completely phentolamine-sensitive.
These data suggest the presence of multiple types of
vasoconstrictor constituents like phentolamine sensitive
and insensitive, which needs further studies to
characterize. It was interesting to note that despite the
presence of vasoconstrictor constituents both in parent
formulation and most of its ingredients, these did not
increase blood pressure in anaesthetized rats, which
might be because of the dominant role of endogenous
mediators in intact body systems offering blockade to
vasoconstrictor constituents. On the other hand, the co-
existence of strong vasorelaxant and cardio depressant
elements in the parent formulation and its ingredients
may not be allowing the expression of vasoconstrictor
elements to dominate and cause hypertension in the in
vivo system.
To determine cardio-suppressant activity contributing
in attenuating cardiac output, when the parent formula-
tion and its ingredients were tested on spontaneously
beating atrial preparations of guinea-pigs, POL4 and
three of its ingredients showed exclusively negative
inotropic and chronotropic effects similar to the effect
of verapamil. However, N. sativa showed mild cardiac
stimulation in terms of an increase in the force of con-
traction, which is also in support to its medicinal use as
cardiac stimulant in the form of a formulation (Lubub-
Al-Asrar) [16]. The probable mechanism likely to be
involved in cardio-depressant activities seems Ca++ an-
tagonist pathway, while mild cardiac stimulant effect on
the part of N. sativa needs further exploration to con-
firm. The standard Ca++ antagonist like verapamil which
is known to lower blood pressure [48, 49] partly by caus-
ing cardiac suppression via inhibition of inward slow
current at the time of action potential [50]. The ob-
served cardiac inhibitory effect of the test material(s)
might be attenuating cardiac output leading to a
decrease in the blood pressure. Our findings are in line
with the cardiac inhibitory effect of medicinal plants
causing reduction in the cardiac output, thus resulting
in decreased blood pressure [15, 43, 51–53]. In sum-
mary, it appears that nature has composed the opposing
mechanisms not allowing the vasodilator effect to cross
the desired limit thus overriding excessive drop in blood
pressure, which has usually been observed when using
standard antihypertensive drugs [45]. The co-existence
of components with combating activities have been
found common in many plants like Viola odorata [43],
Carthamus oxycantha [47], Curcuma long [54], Acorus
calamus [55] and piperine, an alkaloid of Piper longum
and Piper nigrum [56] and is also in agreement with the
concept that natural products in their original form
possess synergistic and/or side effects nullifying combi-
nations [11]. Varied distribution of total phenolic and
flavonoid in POL4 and its constituents is also providing
strength to their cardiovascular benefits as phenolic and
flavonoids are known for their effectiveness in cardiovas-
cular disorders [50, 57, 58]. On the other hand, these
findings suggest that excluding G. sylvestre from POL4
formulation may result in a better product with i-
mproved efficacy in treating hypertension.
Table 5 Percentage maximal response of Ca++ (% Emax) without
and with test materials in rat aortic tissues
Test materials Concentration % Emax of Ca
++ ±
SEM, n = 4–7
P value
Control - 100 ± 0 -
POL4.Cr (mg/ml) 1 52.66 ± 8.62 p < 0.001
3 25.66 ± 3.18 p < 0.001
Verapamil (μM) 0.03 63.85 ± 4.00 p < 0.001
0.1 18.65 ± 4.09 p < 0.001
Ci.Cr (mg/ml) 0.1 62.33 ± 3.84 p < 0.001
0.3 49.00 ± 4.00 p < 0.001
Gs.Cr (mg/ml) 3 68.33 ± 4.41 p < 0.001
5 17.93 ± 5.50 p < 0.001
Ns.Cr (mg/ml) 0.03 73.00 ± 3.39 p < 0.001
0.1 37.00 ± 2.38 p < 0.001
Tfg.Cr (mg/ml) 0.3 62.33 ± 4.33 p < 0.001
1 33.33 ± 7.26 p < 0.001
p-value were obtained by comparing the concentration–response curves of Ca
++ in the absence (control) and presence of respective test material(s) using
two-way analysis of variance (ANOVA) followed by Bonferroni’s
post-test correction
Abbreviations: POL4.Cr the crude extract of poly herbal formulation, Ci.Cr the
crude extract of C. intybus, Gs.Cr the crude extract of G. sylvestre, Ns.Cr the
crude extract of N. sativa, Tfg.Cr the crude extract of T. foenum graecum
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Conclusions
This study indicates that POL4 and its ingredients pos-
sess blood pressure lowering effect predominantly medi-
ated through inhibition of Ca++ influx via membranous
Ca++ channels and receptor (α-adrenergic) operated
pathways. The additional presence of vasoconstrictor
agents (partially phentolamine-sensitive) in parent for-
mulation possibly because of G. sylvestre and N. sativa
may be meant to suppress the excessive hypotension, a
known adverse effect associated with the use of antihy-
pertensive drugs when used at higher doses and/or for
longer duration. Thus, this study provides a rationale to
the medicinal use of POL4 and its ingredients in cardio-
vascular disorders like hypertension.
Abbreviations
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(80 mM); i.p: intraperitoneally; MAP: Mean arterial pressure; Ns.Cr: Aqueous
methanolic extract of Nigella sativa; POL4.Cr: Aqueous methanolic extract of
polyherbal formulation; ROCs: Receptor-operated channels; Tfg.Cr: Aqueous
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